The global brain metastasis therapeutics market is poised for significant growth, with an anticipated compound annual growth rate (CAGR) of 7.8% over the forecast period. As of 2023, the market is valued at USD 3,269.8 million and is projected to expand to USD 6,915.2 million by 2033.
The sweeping rate of cancer incidences is pushing the probability of brain metastasis. Thus, contributing to the brain metastasis therapeutics industry growth. To bring efficiency to diagnostic technology, companies are enhancing their diagnostic techniques like positron emission tomography (PET), magnetic resonance imaging (MRI), and molecular profiling. Due to their precise diagnosis and early detection of brain metastasis, healthcare providers can timely initiate treatment.
As patients suffering from brain metastasis appear to multiply, treatment modalities exhibit constant evolution. Some of these modalities include immunotherapy, stereotactic radiosurgery, and targeted therapies. They significantly enhance patient outcomes for brain metastasis. For more effective patient outcomes, end users have started giving options for personalized treatment plans.
Increasing healthcare budgets and better access to medical facilities in developing economies are expected to attract top vendors for possible growth.
Pharmaceutical firms, academic centers, and research institutes are collaborating to develop new treatment approaches and expedite the advancement of brain metastasis therapeutics. Concerted efforts are expected to promote knowledge sharing, research funding, and access to resources, and propel market growth.
Top Highlights from the FMI’s Analysis of the Brain Metastasis Therapeutics Market:
- North America contributed a gigantic share of 35% in the historical period. The region is expected to tread on the same trend over the forecast period. Increasing clinical trials and novel drug development for brain metastasis are expected to enhance the treatment options and drive positive outcomes for patients.
- Within North America, the United States market is expected to record a 30.9% share. The country is expected to observe prime time, as patients across the globe are seeking superior quality medical treatment. Additionally, manufacturers are crowding the country to gain from the said trend.
- Europe is another key region for brain metastasis therapeutics, sharing 24.5% of the global market. Due to government support, heightened technological innovations, and increasing cases of brain metastasis, enterprises residing or entering the region are expected to observe several growth prospects.
- Germany’s stake in the market was 5.7% in 2022. The efficient healthcare system in the country is expected to support the country’s growth.
- Due to the large pool of geriatric people susceptible to brain metastasis, Japan is expected to offer lucrative opportunities for manufacturers.
- China is expected to thrive in the upcoming years, as FMI anticipates that the country is going to witness a 9.8% CAGR from 2023 to 2033. Enterprises can most benefit from expanding their business into developing countries to meet the increasing demand for brain metastasis therapeutics.
- Australia is yet another country observing a high growth of 7.8% over the forecast period. The country offers significant opportunities for businesses to foray into the market.
- For treatment, patients mostly opt for radiation therapy due to its effective results. In 2022, the radiation therapy segment accounted for 32.1% market share.
- Largely, cancer hospitals deploy brain metastasis therapeutics to treat the related disorder. In 2022, the cancer hospitals segment accounted for 44.9% market share.
Growing Market Interest: Explore Comprehensive Insights and Trends with Our Detailed Report!
Latest Ongoings in the Market: Key Players in the News
- Zion Pharma Limited, a Chinese firm known for its biotechnology, announced its agreement with Roche to innovate and then commercialize oral HER2 tyrosine kinase inhibitor, which is a blood-brain barrier penetrant. The compound can avoid the onset of brain metastases in HER2-positive metastatic breast cancer patients.
- In June 2023, NeOnc Technologies Holdings, Inc. announced that it had received a green light from FDA to advance with Phase 1/2 Trials of NEO212. These trials will address primary brain tumors and brain metastasis, along with offering standard-of-care therapy. The main aim of this trial is to evaluate the preliminary efficacy and safety of NEO212.
- A phase 2 clinical trial of pembrolizumab displays positive results, with data reflecting 42% of metastatic brain cancer patients benefitting from the treatment. However, the research suggests that therapy’s benefits must be weighed against toxicity risks.
Key Companies Profiled:
- Bayer AG
- Pfizer Inc.
- Sanofi
- F. Hoffmann-La Roche Ltd.
- Eli Lilly & Company
- Novartis AG
- GlaxoSmithKline
- Merck & Co. Inc.
- AstraZeneca
- AngioChem Inc.
Key Segments Profiled in the Brain Metastasis Therapeutics Market Survey
By Treatment Type:
- Radiation Therapy
- Chemotherapy
- Targeted Therapy
- Anticonvulsants
- Corticosteroids
By End Use:
- Cancer Hospitals
- Clinics
- Cancer Research Centers
By Region:
- North America
- Latin America
- Asia Pacific
- Middle East and Africa
- Europe
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube